January 29, 2023

Healthy About Liver

Masters of Health

Aspira Women’s Health Announces Preliminary Fourth Quarter 2022 Volume, Preliminary Results in Line with Cash Utilization Guidance, and Other Highlights

Aspira Women’s Health Inc.

Preliminary screening volume all through the fourth quarter of 2022 was 5,643, an enhance of 18 % compared to the fourth quarter of 2021

Preliminary success regular with formerly provided hard cash utilization advice for the fourth quarter and full yr of 2022

Even further decreased team to reach predicted yr-around-12 months income value financial savings of about $6 million in 2023

AUSTIN, Texas, Jan. 09, 2023 (World NEWSWIRE) — Aspira Women’s Well being Inc. (“Aspira”), a bio-analytical centered women’s health and fitness business concentrated on the development of gynecologic ailment diagnostic tools, nowadays announced preliminary fourth quarter highlights.

Preliminary Fourth Quarter Highlights

  • The quantity of OvaSuiteSM tests done enhanced 23% to 21,424 assessments throughout the yr ended December 31, 2022, in contrast to 17,377 exams in 2021.

  • The selection of OvaSuite assessments executed greater 18% to 5,643 exams all through the quarter finished December 31, 2022, compared to 4,768 checks for the fourth quarter of 2021.

  • Normal day by day take a look at volume arrived at a new significant in the fourth quarter, rising to 86.6.

  • Preliminary outcomes suggest that Aspira has achieved previously provided cash utilization assistance for the fourth quarter of amongst $6 million and 8 million.

Aspira President and CEO, Nicole Sandford, stated, “This year-over-calendar year raise in examination quantity demonstrates constant provider adoption and the developing rely on in our Ova1Plus® ovarian cancer hazard assessment check. To even further accelerate the trajectory of our OvaSuite product or service portfolio in 2023, we have determined our most impactful sales and marketing and advertising tactics and have manufactured immediate changes to our techniques as a result. Territories have been expanded for our most productive area representatives, and we prepare to produce additional large-touch health practitioner academic chances dependent on the OvaWatch medical study not long ago printed in Frontiers in Drugs . We are also having ways to carry on to enhance our romantic relationship with BioReference following the thriving launch of our co-marketing and advertising and distribution agreement in the fourth quarter.”

Ms. Sandford continued, “We proceed to make progress on price containment, and preliminary results show we easily met our beforehand presented money utilization guidance for the fourth quarter and entire year of 2022. Like the pressure reduction we executed past 7 days, we count on to save more than $6 million dollars, moreover the charge of advantages, in 2023 associated to redundant roles. We do not anticipate these reductions to have a product influence on our expansion strategies. We believe that our current sources and incremental earnings will maintain the enterprise as a result of its product or service innovation and advancement targets in 2023,” Ms. Sandford concluded.

About Aspira Women’s Health and fitness Inc.
Aspira Women’s Health Inc. is reworking women’s gynecological well being with the discovery, enhancement, and commercialization of ground breaking tests choices for girls of all races and ethnicities. OvaSuite is the company’s portfolio of blood-based ovarian cancer danger assessment assessments created to assistance health care vendors go confidently from assessment to action for girls with adnexal masses. Ova1Plus combines our Fda-cleared products, Ova1® and Overa®, to detect chance of ovarian malignancy in women with adnexal masses planned for medical procedures. OvaWatchSM, a lab-made exam with a 99% Negative Predictive Worth, was built to rule out ovarian cancer threat in sufferers with masses that surface benign or indeterminate primarily based on the clinician’s original evaluation. EndoCheckTM, Aspira’s 1st-of-its-sort non-invasive diagnostic examination for endometriosis, is at this time in improvement. Visit our web site for far more information at www.aspirawh.com.

Ahead-Searching Statements
This press launch consists of ahead-searching statements, as described in the Personal Securities Litigation Reform Act of 1995, like statements concerning strategic designs, progress with respect to cost containment, believed test volumes, believed income utilization for the fourth quarter and entire year of 2022, hard cash methods and anticipated discounts and impacts from workforce reductions. Ahead-searching statements require a selection of challenges and uncertainties. Text this kind of as “may,” “expects,” “intends,” “anticipates,” “believes,” “estimates,” “plans,” “seeks,” “could,” “should,” “continue,” “will,” “potential,” “projects” and identical expressions are intended to determine forward-wanting statements. These ahead-looking statements speak only as of the day of this push release and are matter to a number of risks, uncertainties and assumptions, which include all those described in the segment entitled “Risk Factors” in Aspira’s Annual Report on Sort 10-K for the year ended December 31, 2021, as supplemented by the section entitled “Risk Factors” in Aspira’s Quarterly Report on Kind 10-Q for the quarter finished September 30, 2022. Among other issues, there can be no assurance that Aspira’s true comprehensive calendar year 2022 economical and working effects will not differ, perhaps significantly, from the preliminary economic and running results contained in this push release. In addition, Aspira has not accomplished its fourth quarter and complete yr 2022 closing and review procedure, and the last results for the full calendar year 2022 may well vary, perhaps substantially, from the statements produced in this press release. For the duration of the program of making ready our 2022 economic statements and through our evaluate system, we could establish things that would require us to make changes that might be substance to the quantities described in this press launch. True success may perhaps also vary from those people contemplated by forward-on the lookout statements due to threats like, but not restricted to: our capacity to continue as a going issue our capability to comply with Nasdaq’s ongoing listing necessities impacts ensuing from opportunity alterations to protection of Ova1 by means of our Medicare Administrative Carrier for Ova1 impacts ensuing from or relating to the COVID-19 pandemic and steps taken to have it expected use of capital and its effects our capacity to improve the volume of our merchandise income failures by third-occasion payers to reimburse for our goods and products and services or modifications to reimbursement charges our skill to carry on developing current systems and to acquire, safeguard and boost our proprietary systems ideas to establish and complete laboratory developed exams our means to comply with Foods and Drug Administration (“FDA”) regulations that relate to our solutions and to receive any Fda clearance or approval needed to create and commercialize clinical products our capacity to develop and commercialize additional diagnostic merchandise and attain market acceptance with regard to these merchandise our skill to compete effectively our skill to receive any regulatory acceptance essential for our potential diagnostic products or our suppliers’ skill to comply with Fda necessities for production, advertising and post-sector checking of our products our capability to preserve enough or satisfactory supplies of immunoassay kits from our suppliers in the celebration that we triumph in commercializing our items outside the house the United States, the political, financial and other circumstances impacting other international locations variations in healthcare policy our potential to comply with environmental legislation our ability to comply with the added regulations and laws that use to us in connection with the operation of ASPiRA LABS our capability to use our internet running decline carryforwards our means to use mental house our means to efficiently protect our proprietary engineering versus third functions our ability to receive licenses in the occasion a 3rd party efficiently asserts proprietary legal rights the liquidity and trading quantity of our typical stock the concentration of possession of our typical inventory our means to keep key staff members our capacity to safe added cash on appropriate terms to execute our organization system organization interruptions the efficiency and availability of our information and facts programs our capability to integrate and achieve expected benefits from any acquisitions or strategic alliances upcoming litigation from us, like infringement of mental house and product legal responsibility publicity and supplemental fees that might be demanded to make additional enhancements to our laboratory functions. The activities and situation mirrored in Aspira’s ahead-on the lookout statements may possibly not be achieved or come about, and genuine success could vary materially from those projected in the forward-searching statements. Aspira expressly disclaims any obligation to update, amend or explain any forward-hunting statements no matter if as a final result of new data, foreseeable future functions or normally, besides as needed by regulation.

Investor Relations Contact:
Monique Kosse
Managing Director
LifeSci Advisors, LLC
Tel: 212-915-3820